论文部分内容阅读
rh IL- 2是肿瘤治疗中最常用的细胞因子 ,我们对 2 1例恶性肿瘤患者进行了大剂量 rh IL- 2 期临床应用疗效观察 ,现将结果报告如下。1 材料与方法1 .1 研究对象正常对照组 30例 ,均为健康查体者。男性 1 1例 ,女性 1 9例 ;平均年龄 37.6± 4.9岁。恶性肿瘤组2 1例 ,均经病理
Rh IL-2 is the most commonly used cytokine in the treatment of cancer. We have observed the clinical efficacy of large doses of rh IL-2 in 21 patients with malignant tumors. The results are reported below. 1 Materials and Methods 1.1 The subjects in the normal control group were 30 cases and all were healthy examiners. There were 11 males and 19 females; the average age was 37.6±4.9 years. In the malignant tumor group, 21 cases were pathological